Eltrombopag

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Eltrombopag and local guidelines before prescribing.

Thrombopoietin agonist

Mechanism

Thrombopoietin receptor agonist.

Uses

Chronic ITP, aplastic anaemia, hepatitis C thrombocytopenia.

Dosing

No dose is given in the chapters. See the BNF.

Side effects

Hepatotoxicity, thrombosis, cataracts, headache.

Interactions

Polyvalent cations reduce absorption (separate by 4 hours).

Contraindications and cautions

Liver disease caution

Monitoring

Platelets, LFT

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

Reduce dose in hepatic impairment and East Asian ancestry

Overdose and reversal

Supportive

Special advice

Monitor LFT and platelets; do not normalise platelet count.

More from the textbook: uses, cautions and other points
Where it is discussed in the book